Venture Capital
Avalon BioVentures
Avalon BioVentures backs early-stage and high-growth companies, typically pre-profit, from San Diego, California, USA. It states a focus on healthcare & life sciences.
SEC filings
What Avalon BioVentures has raised
From this firm's own Form D filings. A fund files one within fifteen days of its first sale, under penalty of perjury, which makes these the hardest numbers on the page.
| Vehicles filed | 3 |
| Total capital raised | $66m |
| Largest single vehicle | $45m |
| Filing history | 2021 to 2022 |
| Smallest accepted commitment | None stated |
| Filed from | CALIFORNIA |
Form D covers US-domiciled vehicles raised from accredited investors. It will not capture a fund raised outside the United States, separately managed accounts, or capital deployed off balance sheet, so treat these as a floor rather than a total.
Regulatory record
How Avalon BioVentures is registered
From this firm's Form ADV, the annual filing every registered and exempt investment adviser makes to the SEC.
| Adviser status | Exempt reporting adviser |
| Regulatory assets under management | Not reported by an ERA |
| Private funds advised | 1 · $128m gross |
| SEC adviser number | CRD 316674 |
An exempt reporting adviser is not required to report regulatory assets under management, so the blank above means the question was not asked rather than that the answer is unknown. Where a figure exists it is the gross asset value of the private funds the firm advises, which is a different and usually larger measure.
Portfolio
Disclosed holdings
Companies Avalon BioVentures lists on its own website. No investment years are published. 2 have a recorded transaction against them in the deal archive.
| Company | Invested | Years held | Recorded transaction |
|---|---|---|---|
| Acquisition News Article | — | — | — |
| Afraxis | — | — | — |
| Ambit Biosciences | — | — | $315m 2014 |
| Aratana | — | — | — |
| Calporta Therapeutics | — | — | $576m 2019 |
| Corporate | — | — | — |
| Enlaza Therapeutics | — | — | — |
| Janux | — | — | — |
| Nerio | — | — | — |
| Press Release | — | — | — |
| Sitari | — | — | — |
| Synthorx | — | — | — |
| X-Ceptor Therapeutics | — | — | — |
| Xenopharm | — | — | — |
| Zacharon | — | — | — |
Compiled from Avalon BioVentures’s published portfolio page. Where a recorded transaction is shown, that company was the target of a reported deal and has most likely already been realised. Nothing here is represented as being for sale.
Valuation context
Transaction values in Healthcare & Life Sciences
What companies have actually sold for in healthcare & life sciences, across 1,263 recorded transactions.
The full healthcare & life sciences picture - most active acquirers, recent transactions and every investor in the sector.
For owners
Own a healthcare & life sciences business?
The investors on this page acquire companies like yours. A confidential valuation costs nothing, commits you to nothing, and nobody is told you asked.
Request a confidential valuationFor investors
Is this Avalon BioVentures?
Claim this profile to correct anything wrong and tell us what you are looking for. We will send matching opportunities as they arise.
Claim or correct this profileTargeted buyer search
Which hundred of these would actually buy your business?
A researched shortlist with a verified deal-team contact for each, and the reason it is on the list. Fixed fee, from $1,450 - or we make the approach for you and hand you the conversations.
Comparable investors
Similar mandates
Other venture capital investors active in healthcare & life sciences.